Literature DB >> 19448843

HIV latency: present knowledge, future directions.

Xavier Contreras1, Tina Lenasi, B Matija Peterlin.   

Abstract

Current therapies do not eradicate HIV from infected patients. Indeed, HIV hides in a latent form insensitive to these therapies. Thus, one priority is to purge these latent reservoirs. But what mechanisms are responsible for latency and what are the reservoirs of latently infected cells? The present knowledge in terms of HIV latency is still incomplete and current therapeutic strategies fail to eradicate completely latently infected cells. What could the future bring?

Entities:  

Year:  2006        PMID： 19448843      PMCID： PMC2682531          DOI： 10.2217/17460794.1.6.733

Source DB:  PubMed          Journal:  Future Virol        ISSN： 1746-0794            Impact factor:   1.831


  68 in total

1.  Macrophages archive HIV-1 virions for dissemination in trans.

Authors:  Natalia Sharova; Catherine Swingler; Mark Sharkey; Mario Stevenson
Journal:  EMBO J       Date:  2005-05-26       Impact factor: 11.598

2.  Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry.

Authors:  K Takahashi; S L Wesselingh; D E Griffin; J C McArthur; R T Johnson; J D Glass
Journal:  Ann Neurol       Date:  1996-06       Impact factor: 10.422

Review 3.  HIV-I Tat: a polypeptide for all seasons.

Authors:  A Rubartelli; A Poggi; R Sitia; M R Zocchi
Journal:  Immunol Today       Date:  1998-12

4.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.

Authors:  M K Lewinski; D Bisgrove; P Shinn; H Chen; C Hoffmann; S Hannenhalli; E Verdin; C C Berry; J R Ecker; F D Bushman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1.

Authors:  Haihong Zhong; Michael J May; Eijiro Jimi; Sankar Ghosh
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

7.  The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.

Authors:  Lakshmanan Ganesh; Ezra Burstein; Anuradha Guha-Niyogi; Mark K Louder; John R Mascola; Leo W J Klomp; Cisca Wijmenga; Colin S Duckett; Gary J Nabel
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

8.  Catalytic site-specific cleavage of a DNA-target by an oligonucleotide carrying bleomycin A5.

Authors:  D S Sergeyev; T S Godovikova; V F Zarytova
Journal:  Nucleic Acids Res       Date:  1995-11-11       Impact factor: 16.971

9.  Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

Authors:  M Andreeff; R Stone; J Michaeli; C W Young; W P Tong; H Sogoloff; T Ervin; D Kufe; R A Rifkind; P A Marks
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

10.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728
View more
  10 in total

1.  Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Authors:  Koen Bartholomeeusen; Koh Fujinaga; Yanhui Xiang; B Matija Peterlin
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

2.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

3.  Transcriptional interference antagonizes proviral gene expression to promote HIV latency.

Authors:  Tina Lenasi; Xavier Contreras; B Matija Peterlin
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

4.  Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.

Authors:  Xavier Contreras; Marc Schweneker; Ching-Shih Chen; Joseph M McCune; Steven G Deeks; Jeffrey Martin; B Matija Peterlin
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

Review 5.  New insights into the control of HIV-1 transcription: when Tat meets the 7SK snRNP and super elongation complex (SEC).

Authors:  Nanhai He; Qiang Zhou
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-01       Impact factor: 4.147

6.  Activation of LTRs from different human endogenous retrovirus (HERV) families by the HTLV-1 tax protein and T-cell activators.

Authors:  Chirine Toufaily; Sebastien Landry; Christine Leib-Mosch; Eric Rassart; Benoit Barbeau
Journal:  Viruses       Date:  2011-11-02       Impact factor: 5.048

7.  PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread.

Authors:  Xiaolong Tang; Yong Liang; Xinkuang Liu; Shuping Zhou; Liang Liu; Fujina Zhang; Chunmei Xie; Shuyu Cai; Jia Wei; Yongqiang Zhu; Wei Hou
Journal:  Nanoscale Res Lett       Date:  2015-10-22       Impact factor: 4.703

8.  Fluctuations in Tat copy number when it counts the most: a possible mechanism to battle the HIV latency.

Authors:  Zoran Konkoli; Aldo Jesorka
Journal:  Theor Biol Med Model       Date:  2013-03-05       Impact factor: 2.432

9.  HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.

Authors:  Xavier Contreras; Matjaz Barboric; Tina Lenasi; B Matija Peterlin
Journal:  PLoS Pathog       Date:  2007-10-12       Impact factor: 6.823

10.  HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters.

Authors:  Sebastian Eilebrecht; Valentin Le Douce; Raphael Riclet; Brice Targat; Houda Hallay; Benot Van Driessche; Christian Schwartz; Gwenaëlle Robette; Carine Van Lint; Olivier Rohr; Arndt G Benecke
Journal:  Nucleic Acids Res       Date:  2014-03-11       Impact factor: 16.971
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.